BioInvent International
ISIN: SE0015244520 | Ticker: BINV | LEI: 549300E7QRHEF2IJUY10
Country: Sweden
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.
93
HeadquartersIdeongatan 1, 22362 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|---|
| Assets | N/A | N/A | 802,640,000.00 | N/A | 1,447,311,000.00 | N/A | 1,712,214,000.00 |
| Noncurrent Assets | N/A | N/A | 29,596,000.00 | N/A | 331,292,000.00 | N/A | 628,152,000.00 |
| Office Equipment | N/A | N/A | 16,182,000.00 | N/A | 21,395,000.00 | N/A | 24,880,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 0.00 | N/A | 0.00 | N/A | 0.00 |
| Current Assets | N/A | N/A | 773,044,000.00 | N/A | 1,116,019,000.00 | N/A | 1,084,062,000.00 |
| Inventories | N/A | N/A | 4,079,000.00 | N/A | 16,848,000.00 | N/A | 11,506,000.00 |
| Current Trade Receivables | N/A | N/A | 29,920,000.00 | N/A | 370,000.00 | N/A | 15,780,000.00 |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | N/A | N/A | N/A | 6,948,000.00 | N/A | 18,498,000.00 |
| Cash and cash equivalents | N/A | 153,975,000.00 | 729,270,000.00 | 729,270,000.00 | 910,755,000.00 | 910,755,000.00 | 515,047,000.00 |
| Equity And Liabilities | N/A | N/A | 802,640,000.00 | N/A | 1,447,311,000.00 | N/A | 1,712,214,000.00 |
| Equity | 169,436,000.00 | N/A | 743,499,000.00 | N/A | 1,366,987,000.00 | N/A | 1,606,122,000.00 |
| Issued Capital | N/A | N/A | 78,752,000.00 | N/A | 11,694,000.00 | N/A | 12,994,000.00 |
| Retained Earnings | N/A | N/A | -1,817,317,000.00 | N/A | -2,094,623,000.00 | N/A | -2,135,337,000.00 |
| Additional Paidin Capital | N/A | N/A | 2,482,063,000.00 | N/A | 3,449,915,000.00 | N/A | 3,728,464,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 743,499,000.00 | N/A | 1,366,987,000.00 | N/A | 1,606,122,000.00 |
| Noncurrent Liabilities | N/A | N/A | 5,632,000.00 | N/A | 21,532,000.00 | N/A | 18,773,000.00 |
| Current Liabilities | N/A | N/A | 53,509,000.00 | N/A | 58,792,000.00 | N/A | 87,319,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | N/A | 16,913,000.00 | N/A | 19,720,000.00 | N/A | 41,346,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | N/A | N/A | 23,201,000.00 | N/A | 31,972,000.00 |
| Other Current Payables | N/A | N/A | 8,016,000.00 | N/A | 9,036,000.00 | N/A | 5,811,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 147,372,000.00 | 19,384,000.00 | 326,126,000.00 |
| Profit Loss From Operating Activities | -75,474,000.00 | -278,350,000.00 | -50,921,000.00 |
| Finance Income | 625,000.00 | 623,000.00 | 9,212,000.00 |
| Finance Costs | 1,484,000.00 | 717,000.00 | 794,000.00 |
| Profit Loss Before Tax | -76,333,000.00 | -278,444,000.00 | -42,503,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | N/A |
| Profit (loss) | -76,333,000.00 | -278,444,000.00 | -42,503,000.00 |
| Line item in (sek) | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|---|---|
| Profit (loss) | -76,333,000.00 | N/A | -278,444,000.00 | N/A | -42,503,000.00 | N/A |
| Adjustments For Decrease Increase In Inventories | 1,301,000.00 | N/A | -12,769,000.00 | N/A | 5,342,000.00 | N/A |
| Adjustments For Depreciation And Amortisation Expense | 12,004,000.00 | N/A | 14,610,000.00 | N/A | 14,724,000.00 | N/A |
| Other Adjustments For Noncash Items | -41,000.00 | N/A | 1,138,000.00 | N/A | 1,789,000.00 | N/A |
| Interest Paid Classified As Operating Activities | 335,000.00 | N/A | 517,000.00 | N/A | 650,000.00 | N/A |
| Interest Received Classified As Operating Activities | 28,000.00 | N/A | 248,000.00 | N/A | 606,000.00 | N/A |
| Cash Flows From Used In Operating Activities | -62,622,000.00 | N/A | -245,843,000.00 | N/A | -41,227,000.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 6,700,000.00 | N/A | 13,260,000.00 | N/A | 12,377,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -6,700,000.00 | N/A | -467,542,000.00 | N/A | -628,848,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | 5,820,000.00 | N/A | 5,924,000.00 | N/A | 6,362,000.00 | N/A |
| Cash Flows From Used In Financing Activities | 644,617,000.00 | N/A | 894,870,000.00 | N/A | 273,487,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 575,295,000.00 | N/A | 181,485,000.00 | N/A | -396,588,000.00 | N/A |
| Cash and cash equivalents | 729,270,000.00 | 153,975,000.00 | 910,755,000.00 | 729,270,000.00 | 515,047,000.00 | 910,755,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 30.06.23 | Sylvie Ryckebusch | Other | Buy | EUR 7,890.00 |
| 16.11.22 | Dharminder Chahal | Other | Buy | SEK 352,500.00 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 109,798.92 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 27,200.00 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 25,425.00 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 20,700.68 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 17,193.20 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 16,800.00 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 13,712.00 |
| 09.03.22 | Martin Welschof | Other | Buy | SEK 11,205.74 |
SE0015244520
LEI549300E7QRHEF2IJUY10
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.